| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC2377 | Gsk299115a | Novel inhbitor of protein kinase GRK1/2/5 and PKA |
|
| DCC2378 | Gsk-3008348-n1-methyl | Novel quaternized GSK-3008348 derivative, acting as a highly selective αvβ6 Integrin Inhibitor |
|
| DCC2379 | Gsk3038548a | Novel potent RORγ inverse agonist |
|
| DCC2380 | gsk314181a | Potent and selective antagonist of P2X7 receptor |
|
| DCC2381 | Gsk317354a | Novel selective inhibitor of G protein-coupled receptor kinase 2 (GRK2) |
|
| DCC2382 | Gsk3182571 | Promiscuous kinase inhibitor, a close analog of CTx-0294885 |
|
| DCC2383 | Gsk3277329 | Novel agonist of toll-like receptor 2 (TLR2), stimulating the release of G-CSF in activated THP-1 cells, peripheral blood mononuclear cells, and human umbilical vein endothelial cells |
|
| DCC2384 | Gsk334429 | Novel selective non-imidazole histamine H 3 receptor antagonist |
|
| DCC2385 | Gsk-354 | Novel lysine specific histone demethylase 1 (LSD1) inhibitor, exhibiting high selectivity to LSD1 over MAOs |
|
| DCC2386 | Gsk360a | Novel inhibitor of prolyl hydroxylase (PHD) domain-containing enzyme |
|
| DCC2387 | Gsk366a | Novel anti-TB agent against Mycobacterium tuberculosis and Mycobacterium bovis BCG, targeting MmpL3 and inhibiting EchA6 |
|
| DCC2388 | Gsk3830052 | Novel DNMT1-selective inhibitor (IC 50 = 0.11 ± 0.02 µM) |
|
| DCC2389 | Gsk3i Xv | Novel highly potent cell-permeable, reversible, ATP-competitive inhibitor of GSK-3 (IC50 = 0.4 and 0.6 nM for GSK-3α and GSK-3β, respectively) |
|
| DCC2390 | Gsk3-in-38 Featured | GSK3-IN-3 is a mitophagy inducer, inducing Parkin-dependent mitophagy. GSK3-IN-3 is also a GSK-3 inhibitor with an IC50 value of 3.01 μM. GSK3-IN-3 is non-ATP nor substrate competitive and is neuroprotective against 6-OHDA. |
|
| DCC2391 | Gsk3-in-40 | Potent and irreversible inhibitor of GSK3 |
|
| DCC2392 | Gsk-3ß/hdac Inhibitor C11 | First-in-Class GSK-3β/HDAC Dual Inhibitor as a Disease-Modifying Agent To Combat Alzheimer’s Disease |
|
| DCC2393 | Gsk4028 | Negative control for GSK4027 |
|
| DCC2394 | Gsk41364a | Novel specific inhibitor of polo-like kinase 1 (PLK-1), inducing cell death by causing cell cycle arrest at G2/M phase by competing with the ATP binding site of PLK-1 thus leading to apoptosis |
|
| DCC2395 | Gsk452 | Novel, Potent, Selective, and Highly Soluble Bromo and Extraterminal Domain (BET) Second Bromodomain (BD2) Inhibitor |
|
| DCC2396 | Gsk466317a | Novel selective inhibitor of G protein-coupled receptor kinase 2 (GRK2) |
|
| DCC2397 | Gsk557296 | Novel highly potent and selective non-peptide oxytocin receptor antagonist |
|
| DCC2398 | Gsk572a | Novel potent EchA6 inhibitor |
|
| DCC2399 | Gsk5750 | Novel inhibitor of the Ribonuclease H Activity of HIV-1 Reverse Transcriptase |
|
| DCC2400 | Gsk579289a | Potent polo-like kinase 1 (PLK1) inhibitor |
|
| DCC2401 | Gsk635416a | Novel ATM inhibitor with cancer cell specific radiosensitization activity |
|
| DCC2402 | Gsk6776 | Novel, soluble, permeable, and selective BRD7/9 inhibitor |
|
| DCC2403 | Gsk699 | Novel PCAF/GCN5 degrader, modulating PCAF/GCN5 immune cell function through a PROTAC approach |
|
| DCC2404 | Gsk702 | Negative control for GSK699 |
|
| DCC2405 | Gsk716 | Novel stabilizer of Zα 1 -antitrypsin, blocking Zα 1 -antitrypsin polymerisation in vitro, reducing intracellular polymerisation and increasing the secretion of Zα 1 -antitrypsin threefold in an iPSC model of disease |
|
| DCC2406 | Gsk729 | Novel potent inhibitor of EchA6 |
|
